D. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Key Points

• D. Boral Capital reaffirmed a Buy rating on Lineage Cell Therapeutics with a $3 price objective (≈98.9% upside), and analysts' consensus remains Buy with an average target of $6.25.
• The company beat quarterly estimates—$0.00 EPS vs. -$0.07 expected and $6.61M revenue vs. $1.96M expected—but remains unprofitable (ROE -76.13%, net margin -436.47%); shares trade around $1.51 with a market cap of ~$376M.
• Several institutional investors have recently added or increased positions (Defender Capital, Fifth Third, Marshall Wace, Goldman Sachs, Jane Street), and institutions now own about 62.47% of the stock.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating restated by stock analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $3.00 price objective on the stock. D. Boral Capital's target price suggests a potential upside of 98.94% from the stock's current price.

A number of other equities analysts also recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 24th. B. Riley Financial raised their target price on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a "buy" rating in a research note on Wednesday, March 25th. Finally, Canaccord Genuity Group assumed coverage on Lineage Cell Therapeutics in a report on Tuesday, April 28th. They set a "buy" rating and a $9.00 price target on the stock. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $6.25.

Lineage Cell Therapeutics Trading Down 1.4%

Shares of LCTX stock opened at $1.51 on Monday. The business's fifty day simple moving average is $1.64 and its 200-day simple moving average is $1.69. The company has a market cap of $375.94 million, a PE ratio of -5.36 and a beta of 1.60. Lineage Cell Therapeutics has a 12-month low of $0.43 and a 12-month high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.00 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%.The firm had revenue of $6.61 million during the quarter, compared to analysts' expectations of $1.96 million. On average, equities analysts forecast that Lineage Cell Therapeutics will post -0.08 earnings per share for the current year.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Defender Capital LLC. purchased a new stake in Lineage Cell Therapeutics in the fourth quarter valued at approximately $11,405,000. Fifth Third Bancorp purchased a new position in shares of Lineage Cell Therapeutics during the first quarter worth about $7,268,000. Marshall Wace LLP acquired a new stake in Lineage Cell Therapeutics during the 4th quarter worth approximately $2,275,000. Goldman Sachs Group Inc. increased its stake in shares of Lineage Cell Therapeutics by 894.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,438,746 shares of the company's stock worth $2,403,000 after acquiring an additional 1,294,070 shares during the period. Finally, Jane Street Group LLC increased its stake in Lineage Cell Therapeutics by 494.7% in the 4th quarter. Jane Street Group LLC now owns 1,004,794 shares of the company's stock valued at $1,678,000 after purchasing an additional 835,831 shares in the last quarter. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.